Liquiband deal with Stryker

Jul 9, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 3633V
Advanced Medical Solutions Grp PLC
09 July 2009

For Immediate Release

July 2009

Advanced Medical Solutions Group plc

(“AMS” or the Group”)

Global partnership with Stryker for distribution of LiquiBand™ products in Cranio-maxillofacial surgery

WinsfordUK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it has entered into an agreement with Stryker Corporation (“Stryker”) for global marketing and distribution of certain of its LiquiBand™ wound closure products for use in craniomaxillofacial (CMF) surgical procedures. 

Stryker is one of the largest players in the $35.6 billion worldwide orthopaedic market with products sold in more than 120 countries. The CMF segment represents $900m of this market with Stryker being globally recognised as the leader in this specialist field which involves surgical procedures resulting from fracture repair and deformity correction in the head and neck.

Under the terms of the agreement announced today, Stryker will have exclusive marketing and distribution rights for predominantly all geographical markets for CMF, with product launches to the European market, where the products are approved, commencing this month and a phased roll out in the rest of the world following thereafter. Sales by Stryker into the US CMF market are expected to commence later this year following FDA approval of the relevant products. 

LiquiBand™ is a range of topical tissue adhesives based on cyanoacrylate adhesive technology developed for medical applications covering the whole spectrum of wound closure in the Emergency Room (ER) and Operating Room (OR).  Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incisions. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes.

Commenting on this agreementDr. Don Evans, Chief Executive Officer oAdvanced Medical Solutions, stated:

“Given the broad application for the current and future LiquiBand™ product portfolio, we believe that the optimal commercialisation strategy is via multiple partners with specific competencies and experience. I am therefore, delighted that we have been able to sign Stryker as our first global marketing and distribution partner, taking our LiquiBand™ technology into the CMF arena. As a leader in this surgical speciality, they are an ideal partner to create and develop this market for our products.”


For further information, please contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer

Mary Tavener, Finance Director

  Tel: +44 (0) 1606 545508

Buchanan Communications

Mark Court / Stasa Filiplic

Tel: +44 (0) 20 7466 5000

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Richard Jones / Tim Pratelli

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle.  AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.